Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
Clearmind Medicine advanced its Phase I/IIa clinical trial of CMND-100 into the Phase IIa stage for the treatment of Alcohol Use Disorder. Six patients have been enrolled to date across sites in Tel Aviv and Jerusalem, initiating the multiple-dose treatment phase after a positive safety review by an independent Data and Safety Monitoring Board.
Key figures
- Drug Name
- CMND-100
- Phase Of Trial
- Phase IIa
- Patients enrolled
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.